Inhibition of PCSK9 in familial hypercholesterolaemia

The Lancet

Volumn 380, Issue 9836, 2012, Pages 6-7

  Sijbrands, Eric J G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; ATORVASTATIN; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; COLESEVELAM; DALCETRAPIB; EPROTIROME; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MIPOMERSEN; MONOCLONAL ANTIBODY; NICOTINIC ACID; PACTIMIBE; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 SERINE PROTEASE; REGN 727; ROSUVASTATIN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG; AZETIDINE DERIVATIVE; REGN727 MONOCLONAL ANTIBODY;

CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CORONARY RISK; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; NOTE; PRIORITY JOURNAL; FEMALE; HYPERLIPOPROTEINEMIA TYPE 2; MALE;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; AZETIDINES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE;

EID: 84863484894     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60814-9     Document Type: Note

References (13)

1. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008; 29: 2625-33.
2. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Effi cacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337: a2423.
3. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43. (Pubitemid 351482735)
4. Neefjes LA, Ten Kate GJ, Alexia R, et al. Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis 2011; 219: 721-27.
5. Meuwese MC, de Groot E, Duivenvoorden R, et al. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA 2009; 301: 1131-39.
6. Huijgen R, Abbink EJ, Bruckert E, et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther 2010; 32: 615-25.
7. Akdim F, Stroes ES, Sijbrands EJ, et al. Effi cacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 2010; 55: 1611-18.
8. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 998-1006.
9. Zaid A, Roubstova A, Essalmani R, et al. Proprotein convertase subtilisin/ kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 2008; 48: 646-54.
10. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008; 49: 394-98. (Pubitemid 351213624)
11. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18.
12. McKenney JM, Koren, MJ, Kereiakes, DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012; published online March 28. DOI:10.1016/ j.jacc.2012.03.007.
13. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012; published online May 26. DOI:10.1016/S0140-6736(12)60771-5.